Evidence map›Paper›PMID 41102728›Full record

ArticleBMC cancer2025

Tropomodulin 1 is essential for chemotherapy sensitivity and associated with better outcome in triple-negative breast cancer.

Yijie Li, Xinyi Long, Yiting Xie, Xiaorong Zhong, Shiyu Cao, Fei Chen, Mengjia Shen, Lin Xiao, Lijuan Yin, Feng Ye and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yijie LiInstitute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xinyi LongInstitute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yiting XieInstitute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiaorong ZhongInstitute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China.
Shiyu CaoDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Fei ChenDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Mengjia ShenDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Lin XiaoDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Lijuan YinDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Feng YeDepartment of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Ting LuoInstitute of Breast Health Medicine, West China Hospital, Sichuan University, Chengdu, 610041, China. luoting@wchscu.cn.

Funding

Chinese Society of Clinical Oncology Y-HR2020MS-1031/Y-HR2019-0310
6 · The paper itself

Abstract

objectivesTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by poor clinical behaviors and outcomes. TMOD1 was reported as a downstream target of NF-κB contributing to the growth of cancer cells. However, it's impacts on TNBC patients' prognosis and treatment response remain unclear.

methodsThe prognostic value of TMOD1 was analyzed by data from the Kaplan-Meier database and verified through immunohistochemical evaluation from 190 TNBC patients in West China Hospital (WCH). Cell Counting Kit-8 assay, Transwell cell migration assay and Matrigel invasion assay were used for in vitro study. TNBC cells treated with gradient dosage of doxorubicin (Dox), paclitaxel (PTX), and 5-fluorouracil (5-FU) for chemotherapy sensitivity assay. The chemotherapy sensitivity of Dox in vivo was further confirmed by cell line-derived xenograft (CDX) model.

resultsTNBC patients with high TMOD1 expression had longer overall survival (OS) and recurrence-free survival (RFS) in both Kaplan-Meier plotter database and in cohort from WCH. In cellular functional study, overexpression of TMOD1 promoted TNBC cells' proliferation, migration and invasion. It also enhanced TNBC sensitivity to Dox treatment both in vivo and in vitro.

conclusionsHigh TMOD1 expression in TNBC patients is associated with better prognosis. Although TMOD1 expression promotes TNBC cell proliferation, migration, and invasion, TMOD1 enhances the sensitivity to Dox therapy both in vivo and in vitro, which might contribute to improve the prognosis for TNBC patients.

Indexed as

Drug Resistance, NeoplasmTriple Negative Breast NeoplasmsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDoxorubicinFemaleFluorouracilGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMiceMiddle AgedBiomarkers, TumorDoxorubicinFluorouracilPaclitaxelBiomarkerChemotherapyPrognosisTMOD1Triple negative breast cancer

Identifiers

PMID41102728
PMCPMC12533349

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.